<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJFNS</journal-id><journal-title-group><journal-title>Hans Journal of Food and Nutrition Science</journal-title></journal-title-group><issn pub-type="epub">2166-613X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJFNS.2019.81003</article-id><article-id pub-id-type="publisher-id">HJFNS-28546</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJFNS20190100000_15549306.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  牛樟芝菌丝体粉末复方在调节人体血脂之探讨
  Evaluation of Blood Lipid-Lowering Effects of Antrodia cinnamomea Mycelia Powder Complex
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>心彤</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蔡</surname><given-names>文城</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>敞</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>劲初</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>葡萄王生技股份有限公司，台湾 桃园</addr-line></aff><aff id="aff4"><addr-line>上海葡萄王企业有限公司，上海</addr-line></aff><aff id="aff3"><addr-line>台美检验科技有限公司，台湾 新北</addr-line></aff><aff id="aff5"><addr-line>葡萄王生技股份有限公司，台湾 桃园；实践大学食品营养与保健生技学系，台湾 台北；台湾大学食品科技研究所，台湾 台北；中原大学生物科技学系，台湾 桃园</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>14</day><month>01</month><year>2019</year></pub-date><volume>08</volume><issue>01</issue><fpage>17</fpage><lpage>26</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  本试验系参照卫生署「健康食品之调节血脂功能评估方法」，进行牛樟芝菌丝体粉末复方之血脂调节功能评估试验。募集高胆固醇血症患者(TC &gt; 200 mg/dL)进行人体试验，实验设计分组为服用产品的介入组(Intervention group)以及服用以炒熟面粉代替产品的安慰剂组(Placebo group)，依照产品服用指示一天两次、一次两颗的方式持续两个月。于试验前(观察期, Month 0)以及服用产品或安慰剂一个月(介入一个月, Month 1)、两个月(介入两个月, Month 2)三个时间点抽血检测生化项目，记录受试者基本体位以及饮食纪录。试验期间要求受试者不得更改饮食以及运动的习惯，以达到实验的客观性。实验主要是观察受试者于服用产品前后血清(或血浆)中的血脂指标：三酸甘油酯(Triacylglycerol, TG)、总胆固醇(Cholesterol, TC)、高密度脂蛋白胆固醇(High Density Lipoproteins Cholesterol, HDL-C)和低密度脂蛋白胆固醇(Low Density Lipoprotein Cholesterol, LDL-C)是否有改善。同时也会观察其低密度脂蛋白胆固醇氧化延迟时间(LDL oxidative lag time)是否有因产品介入而延长。另一方面，监控受试者的肝功能指数(Glutamate Oxaloacetate Transaminase, GOT、Glutamic Pyruvic Transaminase, GPT)、肾功能指数(Creatinine, Cr、Blood Urea Nitrogen, BUN)以及空腹血糖来评估产品对人体的影响。在观察期(Month 0)，介入组与安慰剂组间无论在基本体位、饮食习惯以及各项血清(或血浆)生化检测数值均无差别。而受试者开始服用产品或安慰剂后，不论是介入一个月(Month 1)或两个月(Month 2)，均可观察到介入组的总胆固醇(TC)以及低密度脂蛋白胆固醇(LDL-C)相较于观察期(Month 0)有显著的减少，且与同一时间的安慰剂组比较也具有显著性的减少(p &lt; 0.05)，三酸甘油酯(TG)和低密度脂蛋白胆固醇氧化延迟时间(LDL oxidative lag time)则无观察到显著的变化。高密度脂蛋白胆固醇(HDL-C)虽然在组间并无显著差异，但与观察期(Month 0)相比是显著的减少，经计算低密度与高密度脂蛋白胆固醇的比例(LDL-C/HDL-C)，显示相较于高密度胆固醇，低密度胆固醇的下降幅度更显著，因此推测高密度脂蛋白胆固醇是伴随着总胆固醇的减少而减少。根据实验结果，在此人体试验模式下，牛樟芝菌丝体粉末复方具有显著改善血中总胆固醇及低密度脂蛋白胆固醇浓度的功效，有助于降低未来心血管疾病发生风险。&lt;br/&gt;Objective: This study was conducted to assess the prenatal developmental blood lipid-lowering effects of an Antrodia cinnamomea mycelia powder complex according to the safety assessment guideline of Health Food announced by Ministry of Health and welfare, Executive Yuan of Taiwan. Methods: A total of 32 hyperlipidemia individuals with TC &gt; 200 mg/dl were randomly divided into intervention group (n = 16) and placebo group (n = 16). Dietary intervention was provided for the intervention group for 2 months. Information on dietary intakes, physical examinations and blood samples was collected. Serum lipids were assayed at baseline and endpoint of the study period. Subjects take two capsules of A. cinnamomea mycelia powder complex or placebo twice a day. The study has 2 weeks run in period, 8 weeks intervention period, and 4 weeks follow-up period. All subjects measure body weight, body fat, blood pressure and biochemical parameters, including triglycerides (TG), total cholesterol (TC), low density lipoprotein in cholesterol (LDL-C), high density lipoprotein in cholesterol (HDL-C), blood sugar, kidney and liver function. Results: The results were found after 8 weeks intervention, the plasma total cholesterol and LDL-C were significantly decreased compared with the initial, and there was significantly difference (p &lt; 0.05) compared with the placebo group. LDL-C/HDL-C and triglyceride level has a decreasing trend. Conclusion: A. cinnamomea mycelia powder complex could decrease blood lipids.
 
</p></abstract><kwd-group><kwd>高血脂，樟芝菌丝体，低密度脂蛋白胆固醇, Hyperlipidemia</kwd><kwd> Antrodia cinnamomea</kwd><kwd> Low Density Lipoprotein Cholesterol</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>牛樟芝菌丝体粉末复方在调节人体 血脂之探讨<sup> </sup></title><p>朱心彤<sup>1</sup>，蔡文城<sup>2</sup>，赵敞<sup>3</sup>，陈劲初<sup>1,4,5,6*</sup></p><p><sup>1</sup>葡萄王生技股份有限公司，台湾 桃园</p><p><sup>2</sup>台美检验科技有限公司，台湾 新北</p><p><sup>3</sup>上海葡萄王企业有限公司，上海</p><p><sup>4</sup>实践大学食品营养与保健生技学系，台湾 台北</p><p><sup>5</sup>台湾大学食品科技研究所，台湾 台北</p><p><sup>6</sup>中原大学生物科技学系，台湾 桃园</p><disp-formula id="hanspub.28546-formula49"><graphic xlink:href="//html.hanspub.org/file/3-1740316x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年1月2日；录用日期：2019年1月13日；发布日期：2019年1月21日</p><disp-formula id="hanspub.28546-formula50"><graphic xlink:href="//html.hanspub.org/file/3-1740316x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>本试验系参照卫生署「健康食品之调节血脂功能评估方法」，进行牛樟芝菌丝体粉末复方之血脂调节功能评估试验。募集高胆固醇血症患者(TC &gt; 200 mg/dL)进行人体试验，实验设计分组为服用产品的介入组(Intervention group)以及服用以炒熟面粉代替产品的安慰剂组(Placebo group)，依照产品服用指示一天两次、一次两颗的方式持续两个月。于试验前(观察期, Month 0)以及服用产品或安慰剂一个月(介入一个月, Month 1)、两个月(介入两个月, Month 2)三个时间点抽血检测生化项目，记录受试者基本体位以及饮食纪录。试验期间要求受试者不得更改饮食以及运动的习惯，以达到实验的客观性。实验主要是观察受试者于服用产品前后血清(或血浆)中的血脂指标：三酸甘油酯(Triacylglycerol, TG)、总胆固醇(Cholesterol, TC)、高密度脂蛋白胆固醇(High Density Lipoproteins Cholesterol, HDL-C)和低密度脂蛋白胆固醇(Low Density Lipoprotein Cholesterol, LDL-C)是否有改善。同时也会观察其低密度脂蛋白胆固醇氧化延迟时间(LDL oxidative lag time)是否有因产品介入而延长。另一方面，监控受试者的肝功能指数(Glutamate Oxaloacetate Transaminase, GOT、Glutamic Pyruvic Transaminase, GPT)、肾功能指数(Creatinine, Cr、Blood Urea Nitrogen, BUN)以及空腹血糖来评估产品对人体的影响。在观察期(Month 0)，介入组与安慰剂组间无论在基本体位、饮食习惯以及各项血清(或血浆)生化检测数值均无差别。而受试者开始服用产品或安慰剂后，不论是介入一个月(Month 1)或两个月(Month 2)，均可观察到介入组的总胆固醇(TC)以及低密度脂蛋白胆固醇(LDL-C)相较于观察期(Month 0)有显著的减少，且与同一时间的安慰剂组比较也具有显著性的减少(p &lt; 0.05)，三酸甘油酯(TG)和低密度脂蛋白胆固醇氧化延迟时间(LDL oxidative lag time)则无观察到显著的变化。高密度脂蛋白胆固醇(HDL-C)虽然在组间并无显著差异，但与观察期(Month 0)相比是显著的减少，经计算低密度与高密度脂蛋白胆固醇的比例(LDL-C/HDL-C)，显示相较于高密度胆固醇，低密度胆固醇的下降幅度更显著，因此推测高密度脂蛋白胆固醇是伴随着总胆固醇的减少而减少。根据实验结果，在此人体试验模式下，牛樟芝菌丝体粉末复方具有显著改善血中总胆固醇及低密度脂蛋白胆固醇浓度的功效，有助于降低未来心血管疾病发生风险。</p><p>关键词 :高血脂，樟芝菌丝体，低密度脂蛋白胆固醇</p><disp-formula id="hanspub.28546-formula51"><graphic xlink:href="//html.hanspub.org/file/3-1740316x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1740316x8_hanspub.png" /> <img src="//html.hanspub.org/file/3-1740316x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>现今饮食型态趋向于高脂低纤，然而此种饮食型态，容易增加血液中低密度脂蛋白胆固醇(Low Density Lipoprotein Cholesterol; LDL-C)浓度，当LDL-C浓度超过130 mg/dL或LDL-C/HDL-C的比值 &gt; 3.5时，LDL-C堆积在血管内皮细胞上，使血管内皮细胞受到伤害，长期堆积造成动脉粥状硬化，成为心血管疾病及脑血管疾病的高危险群 [<xref ref-type="bibr" rid="hanspub.28546-ref1">1</xref>] 。卫生署食品药物管理局公告红曲为具有改善高血脂症功效成份 [<xref ref-type="bibr" rid="hanspub.28546-ref2">2</xref>] ，红曲主要由Monascus spp.发酵而得，在发酵过程中会释放出二级代谢物Monacolin K和γ-Aminobutyric acid (GABA)成分。文献指出红曲能降血压 [<xref ref-type="bibr" rid="hanspub.28546-ref3">3</xref>] 、降低血中胆固醇浓度 [<xref ref-type="bibr" rid="hanspub.28546-ref4">4</xref>] 及抗菌活性 [<xref ref-type="bibr" rid="hanspub.28546-ref5">5</xref>] 。其中Monacolin K能抑制3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase，调节肝脏中胆固醇的生合成 [<xref ref-type="bibr" rid="hanspub.28546-ref6">6</xref>] 。GABA则具有调节生理功能之效用，如：神经传导、调节血压、利尿等作用 [<xref ref-type="bibr" rid="hanspub.28546-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.28546-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.28546-ref9">9</xref>] ，LDL-C 氧化延迟时间与红曲中水溶性抗氧化物、纳豆萃取物、辅酶Q10有关。红曲中水溶性抗氧化物，如： flavonoids及dimerumic acid等物质，能保护脂质，预防氧化，达到抑制LDL-C氧化修饰作用 [<xref ref-type="bibr" rid="hanspub.28546-ref10">10</xref>] 。根据药物研究发现，给予受试者每天60 mg Lovastatin及180 mg辅酶Q10持续六周，可延长5%的LDL-C氧化延迟时间 [<xref ref-type="bibr" rid="hanspub.28546-ref11">11</xref>] ；动物研究发现，给予老鼠low molecular weight viscous substance (LMWS) (Mw &lt; 100,000)的纳豆萃取物，能够抑制LDL-C氧化的情形 [<xref ref-type="bibr" rid="hanspub.28546-ref12">12</xref>] 。牛樟芝菌丝体也在动物实验发现可降低体脂肪，增加油脂代谢 [<xref ref-type="bibr" rid="hanspub.28546-ref13">13</xref>] 。人体实验发现可降低血脂异常患者之LDL-C [<xref ref-type="bibr" rid="hanspub.28546-ref14">14</xref>] ，综合上述的实验证据，证实以上素材具有调节血脂的功效。本研究主要试验牛樟芝菌丝体粉末复方，本研究藉由人体实验的进行来探讨服用产品，是否具有改善高胆固醇血症患者血清(或血浆)中总胆固醇、低密度胆固醇以及三酸甘油酯的血脂调节能力。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 牛樟芝菌丝体粉末制备方法</title><p>牛樟芝菌丝体粉末(A. cinnamomea Mycelia Powder)为购自食品工业发展研究所生物资源与保存中心(新竹市，台湾)之BCRC35398：葡萄王公司自传统发酵干燥获得。牛樟芝培养于1 L PDB培养基中，经25℃、14天培养后，以500 L发酵槽培养，培养基为2%葡萄糖、2%黄豆粉、0.1% yeast extract、0.05% MgSO<sub>4</sub>、0.05% KH<sub>2</sub>PO<sub>4</sub>、25℃、30 rpm培养10~14天发酵全液冷冻干燥备用。</p></sec><sec id="s4_2"><title>2.2. 试验物质</title><p>牛樟芝菌丝体粉末复方包含牛樟芝菌丝体粉末、红曲粉末、纳豆发酵萃取物、姜黄萃取物、辅酶Q10及红景天萃取物，实验前已完成卫生福利部第三类安全性试验。对照物质以炒熟面粉代替试验物质(于后简称为安慰剂)。</p></sec><sec id="s4_3"><title>2.3. 人体试验设计</title><p>经台北医学大学暨附属医院联合人体研究伦理委员会审核通过后，共招募32位受试者，介入与安慰剂组各16位。受试者年龄约在18~75岁之间，甲状腺机能正常，接受抽血筛检，确定血液TC浓度 &gt; 200 mg/dL，参与试验期间，受试者按原饮食习惯摄食，且不得有明显干扰血脂质因子之生活习惯(含运动量改变)。介入组与安慰剂组平行试验，单盲且随机分组。介入组每天共4颗试验物质，于早晚餐后服用，每次2颗；安慰剂组每天摄取相同数量胶囊，形状、颜色、外观同试验物质。试验时间共3个月，包含1个月观察期(Month 0)，2个月介入期(Month 1、2)。</p></sec><sec id="s4_4"><title>2.4. 人体试验执行</title><p>受试者于试验前一晚空腹10小时以上，试验当天早上抽血检验确认受试者是否为高胆固醇血症(血液总胆固醇 &gt; 200 mg/dL)。确认之后，研究人员向受试者说明计划进行步骤与目的，受试者签署同意书后方才纳入实验。于观察期(Month 0)，填写基本资料(年龄、疾病史、用药纪录、活动量)，再进行体位测量(身高、体重、体脂肪)及血压测量；使用采血笔采取空腹微血管血液，以血糖机测量血糖值；并由专业医检师进行抽血(采血部位为上臂静脉)，缴交3日饮食纪录给营养师进行营养评估。研究期间所有血液生化值由台美检验科技有限公司进行分析。于观察期(Month 1、2)，受试者每日服用4颗牛樟芝菌丝体粉末复方或是安慰剂，早晚餐后服用每且次两粒。每个月测量受试者体重、体脂肪、血压、血糖、其他血液生化值，并记录三日饮食摄取量和用药情况，同时于抽血同一天接受营养师咨询。</p></sec><sec id="s4_5"><title>2.5. 检验项目</title><p>监测身高、体重、体脂、血压及血糖。血液生化检查项目：总胆固醇、三酸甘油酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、血清尿素氮、肌酸酐、麸草醋酸转胺酶、麸丙酮酸转胺酶。</p><sec id="s4_5_1"><title>2.5.1. 血清低密度脂蛋白氧化(Serum LDL-C Oxidation)测定</title><p>测量LDL-C对氧化之稳定度，采铜离子诱导LDL-C氧化之延滞期(Lag phase)方法。超高速分离低密度脂蛋白之制备 [<xref ref-type="bibr" rid="hanspub.28546-ref15">15</xref>] ，先以超高速离心机(Beckman Optima TM TLX)离心，取0.4 ml血浆加入0.6 ml密度为1.006 g/ml NaBr溶液置于超高速离心管中，4℃下，以80,000 rpm离心4小时。取浮于最上层部分约 0.4 ml (无色层)，得密度 ≤ 1.006 g/m之VLDL-C，再加入密度1.1485 g/ml之NaBr溶液0.4 ml，4℃下，以80,000 rpm离心4小时。收取浮于最上层部分约0.4 ml (浅黄色层)，得密度 &lt; 1.063 g/ml之LDL-C。LDL-C氧化延迟时间测定(LDL-C oxidation lag time)，以VIVASPIN (50K MWCO)离心管透析LDL-C，将缓冲液置换成pH7.4之Phosphate buffered-saline (PBS)。测定蛋白质浓度并将样品稀释至150 μg/ml，在384孔盘中加入60 L样品与40 μL铜离子溶液(12.5 μg M)诱导LDL-C氧化，以ELISA reader (Biotek EPOCH)于波长232 nm中自动每3分钟之固定时间测定一次其吸光值变化，直至Conjugated dienes生成量达最高，吸光值不再有明显变化为止。计算出诱导低密度脂蛋白氧化之Lag phase (以Propagation phase的切线对X轴之截距代表Lag phase) [<xref ref-type="bibr" rid="hanspub.28546-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.28546-ref17">17</xref>] 。</p></sec><sec id="s4_5_2"><title>2.5.2. 三日饮食记录</title><p>受试者于观察期(Month 0)、介入期(Month 1、2)抽血当周，于周一至周五任选二天、周末或周日任选一天纪录所有饮食摄取量。营养师收得饮食记录本后，成分数据库的营养素分析软件进行营养素分析(御厨皇，台中)。</p></sec></sec><sec id="s4_6"><title>2.6. 统计分析</title><p>利用SAS 9.1版软件进行统计分析，数值以平均值 &#177; 标准偏差表示，使用paired t-test及unpaired t-test 进行组间统计分析，当P &lt; 0.05时代表结果具有统计上的意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 受试者三日饮食纪录</title><p>受试者于抽血当周将进行详细三日饮食纪录，分别纪录一个假日及两个非假日，将饮食纪录以台湾地区食品营养成分数据库的营养素分析软件(御厨皇，台中)进行营养素分析。收集介入组及安慰剂组受试者于观察期(Month 0)、介入期(Month 1、2)两个阶段之三日饮食纪录，见表1，介入组及安慰剂组两组间饮食热量摄取量、三大营养素和占热量百分比以unpaired f-test检定皆无显着差异。以paired f-test检定介入组与安慰剂组于Month 0、Month 1、Month 2之热量、蛋白质、脂质、碳水化合物摄取无显着差异。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Subject three-day diet record</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Item</th><th align="center" valign="middle" >Group</th><th align="center" valign="middle" >Month 0</th><th align="center" valign="middle" >Month 1</th><th align="center" valign="middle" >Month 2</th></tr></thead><tr><td align="center" valign="middle" >Energy (Kcal)</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >1426.1 &#177; 440.6 1468.6 &#177; 459.7</td><td align="center" valign="middle" >1521.1 &#177; 578.7 1610.6 &#177; 459.7</td><td align="center" valign="middle" >1511.9 &#177; 475.0 1700.7 &#177; 781.9</td></tr><tr><td align="center" valign="middle" >Protein (g)</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >57.8 &#177; 15.1 55.7&#177; 26.1</td><td align="center" valign="middle" >53.0 &#177; 15.5 63.7 &#177; 21.0</td><td align="center" valign="middle" >55.1 &#177; 21.9 64.2 &#177; 32.5</td></tr><tr><td align="center" valign="middle" >Lipid (g)</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >50.4 &#177; 21.3 54.1 &#177; 28.9</td><td align="center" valign="middle" >44.2 &#177; 21.2 56.7 &#177;20.0</td><td align="center" valign="middle" >53.7 &#177; 29.5 60.0 &#177; 36.0</td></tr><tr><td align="center" valign="middle" >Carbohydrate (g)</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >183.2 &#177; 68.1 192.0 &#177; 64.9</td><td align="center" valign="middle" >205.0 &#177; 97.6 205.9 &#177; 75.0</td><td align="center" valign="middle" >1187.0 &#177; 54.8 214.3 &#177; 104.6</td></tr><tr><td align="center" valign="middle" >Protein (% of energy)</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >16.6 &#177; 5.8 14.9 &#177; 3.8</td><td align="center" valign="middle" >15.8 &#177; 4.1 16.3 &#177; 3.6</td><td align="center" valign="middle" >15.1 &#177; 1.8 15.6 &#177; 1.8</td></tr><tr><td align="center" valign="middle" >Lipid (% of energy)</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >31.6 &#177; 7.5 31.9&#177; 9.9</td><td align="center" valign="middle" >27.8 &#177; 6.6 31.8 &#177; 6.7</td><td align="center" valign="middle" >31.4 &#177; 10.0 31.6 &#177; 6.4</td></tr><tr><td align="center" valign="middle" >Carbohydrate (% of energy)</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >51.8 &#177; 11.3 53.2 &#177; 11.3</td><td align="center" valign="middle" >56.2 &#177; 8.0 51.8 &#177; 7.2</td><td align="center" valign="middle" >53.5 &#177; 10.7 52.8 &#177; 7.0</td></tr></tbody></table></table-wrap><p>表1. 受试者三日饮食纪录<sup>1</sup></p><p><sup>1</sup>Values are mean &#177; SD.</p></sec><sec id="s5_2"><title>3.2. 受试者基本体位测量</title><p>测量体重、身体质量指数(Body mass index, BMI)、体脂肪、血压。以unpaired t-test检定介入组与安慰剂组两组间之体重、身体质量指数、体脂肪、血压于 Month 0、Month 1、Month 2，皆无显着差异。其中介入组之收缩压Month 0与Month 2相比，由127.94 &#177; 20.5显着下降至119.2 &#177; 22.3 mm/Hg，详见表2。</p></sec><sec id="s5_3"><title>3.3. 受试者血液生化数值</title><sec id="s5_3_1"><title>3.3.1. 肝功能指针</title><p>介入组与安慰剂组之血清GOT、GPT数值在研究期间，数值皆落于正常范围内，以unpaired t-test检定两组间皆无显着差异，见表3。</p></sec><sec id="s5_3_2"><title>3.3.2. 肾功能指针</title><p>介入组与安慰剂组之血液尿素氮BUN、血清肌酸酐Cr数值于研究期间落于正常范围内，以unpaired t-test检定两组间皆无显着差异，见表3。</p></sec><sec id="s5_3_3"><title>3.3.3. 脂质指标</title><p>血清总胆固醇，TC：介入组与安慰剂组之TC浓度于Month 1、Month 2两组间以unpaired t-test检定具显着差异。TC浓度标准范围介于120~200 mg/dL间，介入组之TC浓度在Month 0、Month 1、Month 2 分别为220.8 &#177; 19.0、186.0 &#177; 12.2、194.94 &#177; 29.8 mg/dL，以paired t-test检定发现，产品介入后Month 1、Month 2与Month 0分析比较皆有显着减少，即产品在介入后TC浓度能维持在标准范围120~200 g/dL。安慰剂组Month 2 (234.3 &#177; 31.5 mg/dL)较Month 0显着上升，见表3。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Subject basic position measurement</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Item</th><th align="center" valign="middle" >Group</th><th align="center" valign="middle" >Month 0</th><th align="center" valign="middle" >Month 1</th><th align="center" valign="middle" >Month 2</th></tr></thead><tr><td align="center" valign="middle" >BW (Kg)</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >64.0 &#177; 16.0 57.5&#177; 10.7</td><td align="center" valign="middle" >63.8 &#177; 15.6 57.4 &#177; 11.3</td><td align="center" valign="middle" >63.4 &#177; 15.2 57.2 &#177; 11.2</td></tr><tr><td align="center" valign="middle" >BMI (Kg/m<sup>2</sup>)</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >24.7 &#177; 5.0 22.6 &#177; 3.4</td><td align="center" valign="middle" >24.6 &#177; 4.9 22.6 &#177; 3.6</td><td align="center" valign="middle" >24.4 &#177; 4.7 22.5 &#177; 3.5</td></tr><tr><td align="center" valign="middle" >BF (%)</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >30.0 &#177; 7.5 29.8 &#177; 4.6<sup>a</sup></td><td align="center" valign="middle" >29.1 &#177; 7.5 31.7 &#177; 9.2<sup>ab</sup></td><td align="center" valign="middle" >29.3 &#177; 8.0 28.8 &#177; 5.0<sup>b</sup></td></tr><tr><td align="center" valign="middle" >SBP (mm/Hg)</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >127.9 &#177; 20.5<sup>a</sup> 120.5 &#177; 16.8</td><td align="center" valign="middle" >124.7 &#177; 27.1<sup>ab</sup> 115.3 &#177; 17.7</td><td align="center" valign="middle" >119.2 &#177; 22.3<sup>b</sup> 113.7 &#177; 19.4</td></tr><tr><td align="center" valign="middle" >DBP (mm/Hg)</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >75.9 &#177; 11.3 74.9 &#177; 10.5<sup>a</sup></td><td align="center" valign="middle" >72.3 &#177; 11.5 68.4 &#177; 13.5<sup>b</sup></td><td align="center" valign="middle" >70.9 &#177; 15.6 65.2 &#177; 9.8<sup>b</sup></td></tr></tbody></table></table-wrap><p>表2. 受试者基本体位测量<sup>1</sup></p><p><sup>1</sup>Values are mean &#177; SD. BH, Body height; BW, Body weight; BMI, Body mass index, BW (Kg)/BH (m<sup>2</sup>); BF, Body fat; SBP, Systolic blood pressure; DBP, Diastolic blood pressure. <sup>abc</sup>Values with different superscripts are significantly different at p &lt; 0.05 by paired t-test.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Subject blood biochemical value</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Item</th><th align="center" valign="middle" >参考数值</th><th align="center" valign="middle" >Group</th><th align="center" valign="middle" >Month 0</th><th align="center" valign="middle" >Month 1</th><th align="center" valign="middle" >Month 2</th></tr></thead><tr><td align="center" valign="middle" >GOT (U/L)</td><td align="center" valign="middle" >&lt;45</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >23.9 &#177; 4.7 23.9&#177; 6.7</td><td align="center" valign="middle" >26.5 &#177; 4.9 22.9 &#177; 5.5</td><td align="center" valign="middle" >25.4&#177; 6.9 22.6 &#177; 5.7</td></tr><tr><td align="center" valign="middle" >GPT (U/L)</td><td align="center" valign="middle" >&lt;35</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >25.6 &#177; 9.9 23.1 &#177; 12.6</td><td align="center" valign="middle" >27.1 &#177; 8.3 21.3 &#177; 8.4</td><td align="center" valign="middle" >28.0 &#177; 13.3 21.4 &#177; 7.6</td></tr><tr><td align="center" valign="middle" >BUN (mg/dL)</td><td align="center" valign="middle" >F:7~17 M:9~20</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >13.2 &#177; 3.1<sup>ab</sup> 12.2 &#177; 2.3<sup>a</sup></td><td align="center" valign="middle" >12.5 &#177; 2.9<sup>b</sup> 13.9 &#177; 3.4<sup>a</sup></td><td align="center" valign="middle" >13.6 &#177; 3.9<sup>a</sup> 13.2 &#177; 3.1<sup>ab</sup></td></tr><tr><td align="center" valign="middle" >Cr (mg/dL)</td><td align="center" valign="middle" >F:0.52~1.04 M:0.66~1.25</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >0.8 &#177; 0.2<sup>a</sup> 0.7 &#177; 0.1<sup>a</sup></td><td align="center" valign="middle" >0.7 &#177; 0.2<sup>b</sup> 0.7 &#177; 0.1<sup>b </sup></td><td align="center" valign="middle" >0.7 &#177; 0.2<sup>b</sup> 0.7 &#177; 0.7<sup>a</sup></td></tr><tr><td align="center" valign="middle" >TC (mg/dL)</td><td align="center" valign="middle" >120-200</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >220.8 &#177; 19.0<sup>a</sup> 225.4 &#177; 24.5<sup>b</sup></td><td align="center" valign="middle" >186.0 &#177; 12.2<sup>b</sup> 235.3 &#177; 31.5<sup>ab↑</sup></td><td align="center" valign="middle" >194.9 &#177; 29.8<sup>b</sup> 246.4 &#177; 34.5<sup>a↑</sup></td></tr><tr><td align="center" valign="middle" >TG (mg/dL)</td><td align="center" valign="middle" >35-165</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >120.6 &#177; 45.6 105.4 &#177; 44.7</td><td align="center" valign="middle" >111.4 &#177; 40.6 110.2 &#177; 49.4</td><td align="center" valign="middle" >110.6 &#177; 48.1 119.6 &#177; 61.2</td></tr><tr><td align="center" valign="middle" >HDL-C (mg/dL)</td><td align="center" valign="middle" >&gt;40</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >69.9 &#177; 16.6<sup>a</sup> 71.5 &#177; 16.7<sup>a</sup></td><td align="center" valign="middle" >65.8 &#177; 14.2<sup>b</sup> 69.0 &#177; 13.7<sup>ab</sup></td><td align="center" valign="middle" >63.0 &#177; 11.3<sup>b</sup> 67.2 &#177; 14.3<sup>b</sup></td></tr><tr><td align="center" valign="middle" >LDL-C (mg/dL)</td><td align="center" valign="middle" >&lt;130</td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >146.6 &#177; 25.4<sup>a</sup> 146.8 &#177; 30.9<sup>b</sup></td><td align="center" valign="middle" >101.0 &#177; 18.3<sup>c</sup> 147.8 &#177; 34.7<sup>b↑</sup></td><td align="center" valign="middle" >117.0 &#177; 30.5<sup>b</sup> 162.6 &#177; 32.9<sup>a↑</sup></td></tr><tr><td align="center" valign="middle" >LDL-C/HDL-C</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >2.3 &#177; 0.8<sup>a</sup> 2.2 &#177; 0.8<sup>b</sup></td><td align="center" valign="middle" >1.6 &#177; 0.6<sup>c</sup> 2.3 &#177; 0.7<sup>b↑</sup></td><td align="center" valign="middle" >2.0 &#177; 0.7<sup>b</sup> 2.6 &#177; 0.8<sup>a↑</sup></td></tr><tr><td align="center" valign="middle" >FBS (mg/dL)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >介入组 安慰剂组</td><td align="center" valign="middle" >97.8 &#177; 9.4 95.8 &#177; 5.2</td><td align="center" valign="middle" >99.3 &#177; 9.1 97.7 &#177; 11.9</td><td align="center" valign="middle" >101.1 &#177; 7.6 98.4 &#177; 8.3</td></tr></tbody></table></table-wrap><p>表3. 受试者血液生化值<sup>1</sup></p><p><sup>1</sup>Values are mean &#177; SD. <sup>abc</sup>Values with different superscripts are significantly different at p &lt; 0.05 by paired t-test. <sup>↑</sup>Values with different superscripts are significantly different at p &lt; 0.05 by unpaired t-test.</p><p>三酸甘油酯，TG：介入组与安慰剂组之TG浓度于研究期间，无论是以unpairedt-test检定两组间，或以paired t-test检定各组3个时间点间，皆无发现显着差异，见表3。</p><p>高密度脂蛋白胆固醇浓度，HDL-C：介入组与安慰剂组之HDL-C浓度分别于Month 0、Month 1、Month 2间皆无统计差异，两组间以unpaired f-test检定亦无显着差异，见表3。</p><p>低密度脂蛋白胆固醇浓度，LDL-C：介入组与安慰剂组之LDL-C浓度于Month 1、Month 2两组间以unpaired t-test检定具显着差异。介入组之LDL-C浓度在Month 0、Month 1、Month 2分别为146.6 &#177; 25.4、101.0 &#177; 18.3、117.0 &#177; 30.5 mg/dL，以paired t-test检定发现，Month 1、Month2与Month 0比较皆有显着下降，LDL-C浓度维持在标准范围130 mg/dL内，表示产品在介入后，能降低LDL-C浓度，见表3。</p><p>LDL-C/HDL-C比值：介入组与安慰剂组之LDL-C/HDL-C比值于Month 1、Month 2两组间以unpaired t-test检定具显着差异。介入组之LDL-C/HDL-C比值在Month 0、Month 1、Month 2分别为2.3 &#177; 0.8、1.6 &#177; 0.6、2.0 &#177; 0.7，以paired t-test检定发现，Month 1、Month 2与Month 0比较皆显着下降，表示产品在介入后，能降低LDL-C/HDL-C比值，见表3。</p><p>血糖指标(Fasting blood glucose, FBS)：介入组与安慰剂组之FBS浓度于研究期间，无论是以unpaired f-test检定两组间，或以paired t-test检定各组3个时间点间，皆无发现显着差异，见表3。</p><p>LDL-C Lag time：介入组与安慰剂组之LDL-C Lag time于Month 0、Month 1、Month 2，以unpaired t-test检定表示两组间皆无显着差异。以paired t-test检定介入组之LDL-C Lag time在Month 0 (106.0 &#177; 13.3 mins)与Month 1 (119.9 &#177; 15.4 mins)、Month 2 (118.4 &#177; 9.8 mins)数值，发现Month 1、Month 2数值分别显着高于Month 0，表示介入产品对LDL-C氧化延迟时间不具影响，见图1。</p><p>图1. 受试者各时间点血液中低密度脂蛋白胆固醇氧化延迟时间</p></sec><sec id="s5_3_4"><title>3.3.4. 介入组之TC与LDL-C有效率分析</title><p>介入组受试者之TC变化率在产品介入期间Month 1、Month 2分别为−17.29% &#177; 12.17%、−13.02% &#177; 19.47%，产品有效率分别为87.50%、68.75%，表示产品介入后能有效的降低血中TC浓度。LDL-C变化率则在产品介入期间Month 1、Month 2分别为−30.92% &#177; 6.52%、−20.43% &#177; 14.62%，产品有效率分别为100.00%、81.25%，表示产品介入后能有效的改善血中LDL-C之浓度。另外，介入组不论是在TC变化率与LDL-C变化率，负面效应(adverse effect)在组人数中比例皆不超过20%，因此不影响产品在调节TC浓度与LDL-C浓度的功效宣称，见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Analysis of the efficiency of TC and LDL-C in intervention grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Item</th><th align="center" valign="middle"  rowspan="2"  >Month</th><th align="center" valign="middle"  rowspan="2"  >The rate of change (%)<sup>a</sup></th><th align="center" valign="middle"  colspan="3"  >The effect of treatment<sup>b</sup></th></tr></thead><tr><td align="center" valign="middle" >Positive</td><td align="center" valign="middle" >No</td><td align="center" valign="middle" >Adverse</td></tr><tr><td align="center" valign="middle" >TC</td><td align="center" valign="middle" >M1 M2</td><td align="center" valign="middle" >−17.29 &#177; 12.17 −13.02 &#177; 19.47</td><td align="center" valign="middle" >14 (87.50%) 11 (68.75%)</td><td align="center" valign="middle" >2 (12.50%) 3 (18.75%)</td><td align="center" valign="middle" >0 (0.00%) 2 (12.50%)</td></tr><tr><td align="center" valign="middle" >LDL-C</td><td align="center" valign="middle" >M1 M2</td><td align="center" valign="middle" >−30.92 &#177; 6.52 −20.43 &#177; 14.62</td><td align="center" valign="middle" >16 (100.00%) 13 (81.25%)</td><td align="center" valign="middle" >0 (0.00%) 2 (12.50%)</td><td align="center" valign="middle" >0 (0.00%) 1 (6.25%)</td></tr></tbody></table></table-wrap><p>表4. 介入组之TC与LDL-C有效率分析</p><p><sup>a</sup>Compare with month 0 (baseline). Values are mean &#177; SD. <sup>b</sup>Value present as number (%).</p></sec></sec></sec><sec id="s6"><title>4. 讨论</title><p>本研究为介入组与安慰剂组平行试验，采随机分组、单盲，产品介入前后，每日平均摄取热量和三大营养素摄取量和占热量百分比皆无统计差异，表示二组受试者在实验期间饮食摄取状况并无显着改变。体重、身体质量指数、体脂肪、血压皆与血脂质有关。体重过重、身体质量指数高、体脂肪量多，容易造成高血压或是血中TC、TG、LDL-C浓度增加以及HDL-C浓度减少，导致冠状动脉心脏病的发生 [<xref ref-type="bibr" rid="hanspub.28546-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.28546-ref19">19</xref>] 。本研究为受试者持续服用实验产品2个月，体重、身体质量指数、体脂肪在介入前后均无显着差异(P &gt; 0.05)，表示受试者血液脂质浓度改变可能并非来自体重、身体质量指数、骨体脂肪改变。受试者摄取本研究产品后收缩压显着降低，推测可能与红曲代谢产物之GABA或curcumin有关根据Hsieh及Tai动物研究发现，给予诱发高血压模式大鼠含有1 mg/kg/day GABA之Monascus purpureus M9011萃取物能有效改善血压至正常范围 [<xref ref-type="bibr" rid="hanspub.28546-ref20">20</xref>] ；亦或是curcumin (25 mg/capsule)成分所导致，根据Khajendehi研究指出，每天口服3颗含有curcumin (22.1 mg)成分之胶囊，能有效降低收缩压 [<xref ref-type="bibr" rid="hanspub.28546-ref21">21</xref>] 。介入组受试者之肝功能指针于实验产品介入期间有些微上升的趋势，但是标准偏差值较大且不具统计上意义，推测可能为个体差异造成，例如：受试者熬夜、应酬均会导致血清GOT和GPT浓度上升。并且所有介入组受试者此二项指标浓度均在标准范围内，表示实验产品对肝功能可能不具有伤害性。若肾功能受损，血液BUN及Cr浓度会同时增加，介入组受试者之BUN浓度于产品介入期间Month 2显着上升，然而并未超过建议范围。尿素为蛋白质终产物之一，主要由肾脏排泄。受试者每天由实验产品仅获得0.6克蛋白质，然而受试者研究期间蛋白质摄取量平均值增加8克以上，推测可能为受试者在这段期间饮食蛋白质摄取量增加造成此结果 [<xref ref-type="bibr" rid="hanspub.28546-ref22">22</xref>] 。并且受试者血清Cr浓度于研究期间由0.8 &#177; 0.2 mg/dL (Month 0)显着下降至0.7 &#177; 0.2 mg/dL (Month 1、Month 2)，显示试验产品对肾功能应不具有伤害性。本次试验结果，介入组受试者之TC及LDL-C浓度与介入前相比皆显着改善，TG 浓度则没有显着差异，与过去的研究结果相符。本试验产品主要成分为红曲，其由Monascus purpureus在米中发酵而得，主要的有效成分为Monacolin K，此成分是透过抑制HMG-CoA reductase，使HMG-CoA reductase表现量下降，抑制胆固醇的合成，可降低TC的浓度 [<xref ref-type="bibr" rid="hanspub.28546-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.28546-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.28546-ref25">25</xref>] 。根据挪威 [<xref ref-type="bibr" rid="hanspub.28546-ref26">26</xref>] 、美国 [<xref ref-type="bibr" rid="hanspub.28546-ref27">27</xref>] 、台湾 [<xref ref-type="bibr" rid="hanspub.28546-ref28">28</xref>] 研究指出，给予血脂异常的受试者一天约1200 mg的红曲8~24周，发现有效降低血液中至少14.9%的TC浓度及21.3%的LDL-C浓度，而TG浓度只有在台湾的研究中有显着下降 [<xref ref-type="bibr" rid="hanspub.28546-ref29">29</xref>] 。过去减重研究指出，非糖尿病的代谢症候群肥胖者当体重减轻时，发现TC、LDL-C 浓度显着下降，而HDL-C浓度也有下降的趋势 [<xref ref-type="bibr" rid="hanspub.28546-ref30">30</xref>] [<xref ref-type="bibr" rid="hanspub.28546-ref31">31</xref>] ，在本次研究结果之HDL-C浓度与介入前相比有显着下降的情况，推测可能因为较大幅降低血清TC浓度，造成 HDL-C浓度下降。计算LDL-C/HDL-C比值(动脉粥状硬化危险因子) [<xref ref-type="bibr" rid="hanspub.28546-ref11">11</xref>] 与介入前相比有显着下降，虽然介入组HDL-C浓度随产品介入而有下降的情况，但其LDL-C/HDL-C比值同时也有显着下降的趋势，故表示相较于HDL-C浓度，LDL-C浓度因产品介入下降的幅度更多，因此宣称本产品具有降低LDL-C/HDL-C比值之作用。研究期间介入组与受试者之LDL-C氧化延迟时间比较，产品介入前与介入后相比显着增加，但介入组与安慰剂组相比不具统计意义，表示介入产品对LDL-C氧化延迟时间不具影响。推测若长期服用产品，可能可延长LDL-C氧化延迟时间。</p></sec><sec id="s7"><title>5. 结论</title><p>根据实验结果，在此人体试验模式下，牛樟芝菌丝体粉末复方具有显着改善血中总胆固醇及低密度脂蛋白胆固醇浓度的功效，持续服用产品对肝功能指数(GOT、GPT)、肾功能指数(Cr、BUN)以及空腹血糖浓度(FBS)皆不具影响。有助于降低未来心血管疾病发生风险。</p></sec><sec id="s8"><title>文章引用</title><p>朱心彤,蔡文城,赵 敞,陈劲初. 牛樟芝菌丝体粉末复方在调节人体血脂之探讨Evaluation of Blood Lipid-Lowering Effects of Antrodia cinnamomea Mycelia Powder Complex[J]. 食品与营养科学, 2019, 08(01): 17-26. https://doi.org/10.12677/HJFNS.2019.81003</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.28546-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Lauer, T., Kleinbongard, P., Rath, J., Schulz, R., Kelm, M. and Rassaf, T. (2008) L-Arginine Preferentially Dilates Stenotic Segments of Coronary Arteries Thereby Increasing Coronary Flow. Journal of Internal Medicine, 264, 237-244. &lt;br&gt;https://doi.org/10.1111/j.1365-2796.2008.01943.x</mixed-citation></ref><ref id="hanspub.28546-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">卫生署食品药物管理局. 健康食品规格标准[S], 2010.</mixed-citation></ref><ref id="hanspub.28546-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Tsuji, K., Ichikawa, T., Tanabe, N., Abe, S., Tarui, S. and Nakagawa, Y. (1992) Effects of Two Kinds of Koji on Blood Pressure in Spontaneously Hypertensive Rats. Journal of the Agricultural Chemical Society of Japan, 66, 1241-1246.</mixed-citation></ref><ref id="hanspub.28546-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Endo, A. and Monacolin, K. (1979) A New Hypocholesterolemic Agent Produced by a Monascus Species. The Journal of Antibiotics, 32, 852. &lt;br&gt;https://doi.org/10.7164/antibiotics.32.852</mixed-citation></ref><ref id="hanspub.28546-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Wong, H.C. and Bau, Y.S. (1977) Pigmentation and Antibacterial Activity of Fast Neutron- and X-Ray-Induced Strains of Monascus purpureus Went. Plant physiology, 60, 578-581. &lt;br&gt;https://doi.org/10.1104/pp.60.4.578</mixed-citation></ref><ref id="hanspub.28546-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Cicero, A.F.G., Brancaleoni, M., Laghi, L., Donati, F. and Mino, M. (2005) Antihyperlipidaemic Effect of a Monascus purpureus Brand Dietary Supplement on a Large Sample of Subjects at Low Risk for Cardiovascular Disease: A Pilot Study. Complementary Therapies in Medicine, 13, 273-278. &lt;br&gt;https://doi.org/10.1016/j.ctim.2005.07.008</mixed-citation></ref><ref id="hanspub.28546-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kohama, Y., Matsumoto, S., Mimura, T., Tanabe, N., Inada, A. and Nakanishi, T. (1987) Isolation and Identification of Hypotensive Principles in Red-Moldrice. Chemical &amp; Pharmaceutical Bulletin, 35, 2484-2499.  
&lt;br&gt;https://doi.org/10.1248/cpb.35.2484</mixed-citation></ref><ref id="hanspub.28546-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Tsuji, K., Ichikawa, T., Tanabe, N., Obata, H., Abe, S., Tarui, S. and Nakagawa, Y. (1992) Extraction of Hypotensive Substance from Wheat Beni-Koji. Journal of the Japanese Society for Food Science and Technology, 39, 913-918.  
&lt;br&gt;https://doi.org/10.3136/nskkk1962.39.913</mixed-citation></ref><ref id="hanspub.28546-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ueno, Y., Hayakawa, K., Takahashi, S. and Oda, K. (1997) Purification and Characterization of Glutamate Decarboxylase from Lactobacillus brevis IFO 12005. Bioscience, Biotechnology, and Biochemistry, 61, 1168-1171.  
&lt;br&gt;https://doi.org/10.1271/bbb.61.1168</mixed-citation></ref><ref id="hanspub.28546-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Becker, D.J., Gordon, R.Y., Halbert, S.C., French, B., Morris, P.B. and Rader, D.J. (2009) Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients. Annals of Internal Medicine, 150, 830-839.  
&lt;br&gt;https://doi.org/10.7326/0003-4819-150-12-200906160-00006</mixed-citation></ref><ref id="hanspub.28546-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lin, C.C., Li, T.C. and Lai, M.M. (2005) Efficacy and Safety of Monascus purpureus Went Rice in Subjects with Hyper Lipidemia. European Journal of Endocrinology, 153, 679-686. &lt;br&gt;https://doi.org/10.1530/eje.1.02012</mixed-citation></ref><ref id="hanspub.28546-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Yang, C.W. and Mousa, S.A. (2012) The Effect of Red Yeast Rice (Monascus purpureus) in Dyslipidemia and Other Disorders. Complementary Therapies in Medicine, 20, 466-474. &lt;br&gt;https://doi.org/10.1016/j.ctim.2012.07.004</mixed-citation></ref><ref id="hanspub.28546-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Chang, H.L., Hsu, C.L. and Chen, C.C. (2018) Effect of Antrodia cinnamomea Powder on Obesity in High-Fat Diet-Induced Rats. HANS Journal of Food and Nutrition Science, 6, 244-252.</mixed-citation></ref><ref id="hanspub.28546-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Chen, C.M., Chen, P.N., Cheng, H.Y., Wei, C.C., Ryuji, T., Mitsuko, M. and Kiichiro, M. (2017) Effects of Antrodia cinnamomea Mycelia Extract Containing Antroquinonol on Lowering Low-Density Lipoprotein Cholesterol: A Randomized Double-Blind Study. Journal of Pharmacy and Nutrition Sciences, 7, 73-80.  
&lt;br&gt;https://doi.org/10.6000/1927-5951.2017.07.03.1</mixed-citation></ref><ref id="hanspub.28546-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Chapman, M.J. (1980) Animal Lipoproteins: Chemistry, Structure, and Comparative Aspects. Journal of Lipid Research, 21, 789-853.</mixed-citation></ref><ref id="hanspub.28546-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Kritchevsky, D. (1986) Dietary Fiber and Atherosclerosis.</mixed-citation></ref><ref id="hanspub.28546-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Puhl, H., Waeg, G. and Esterbauer, H. (1994) Methods to Determine Oxidation of Low-Density Lipoproteins. Methods in Enzymology, 233, 425-441. &lt;br&gt;https://doi.org/10.1016/S0076-6879(94)33049-2</mixed-citation></ref><ref id="hanspub.28546-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Mathers, C.D. and Loncar, D. (2006) Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Medicine, 3, 442. &lt;br&gt;https://doi.org/10.1371/journal.pmed.0030442</mixed-citation></ref><ref id="hanspub.28546-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Murray, C.J.L. and Lopez, A.D. (1997) Alternative Projections of Mortality and Disability by Cause 1990-2020: Global Burden of Disease Study. The Lancet, 349, 1498-1504. &lt;br&gt;https://doi.org/10.1016/S0140-6736(96)07492-2</mixed-citation></ref><ref id="hanspub.28546-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Hsieh, P.S. and Tai, Y.H. (2003) Aqueous Extract of Monascus purpureus 9011 Prevents and Reverses Fructose-Induced Hypertension in Rats. Journal of Agricultural and Food Chemistry, 51, 3945-3950.  
&lt;br&gt;https://doi.org/10.1021/jf026157n</mixed-citation></ref><ref id="hanspub.28546-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Khajehdehi, P., Zanjaninejad, B., Aflaki, E., Nazarinia, M., Azad, F., Malekmakan and Dehghanzadeh, G. (2012) Oral Supplementation of Turmeric Decreases Proteinuria, Hematuria, and Systolic Blood Pressure in Patients Suffering from Relapsing or Refractory Lupus Nephritis: A Randomized and Placebo-Controlled Study. Journal of Renal Nutrition, 22, 50-57. &lt;br&gt;https://doi.org/10.1053/j.jrn.2011.03.002</mixed-citation></ref><ref id="hanspub.28546-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Lim, V.S. and Flanigan, M.J. (2001) Protein Intake in Patients with Renal Failure: Comments on the Current NKF DOQI Guidelines for Nutrition in Chronic Renal Failure.</mixed-citation></ref><ref id="hanspub.28546-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Chen, Z.Y., Ma, K.Y., Liang, Y., Peng, C. and Zuo, Y. (2011) Role and Classification of Cholesterol-Lowering Functional Foods. Journal of Functional Foods, 3, 61-69. &lt;br&gt;https://doi.org/10.1016/j.jff.2011.02.003</mixed-citation></ref><ref id="hanspub.28546-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Liu, J., Zhang, J., Shi, Y., Grimsgaard, S., Alraek, T. and Fønnebø, V. (2006) Chinese Red Yeast Rice (Monascus purpureus) for Primary Hyperlipidemia: A Meta-Analysis of Randomized Controlled Trials. Chinese Medicine, 1, 4.  
&lt;br&gt;https://doi.org/10.1186/1749-8546-1-4</mixed-citation></ref><ref id="hanspub.28546-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Man, R.Y.K., Lynn, E.G., Cheung, F., Tsang, P.S.Y. and Karmin, O. (2002) Cholestin Inhibits Cholesterol Synthesis and Secretion in Hepatic Cells (HepG2). Molecular and Cellular Biochemistry, 233, 153-158.  
&lt;br&gt;https://doi.org/10.1023/A:1017487815091</mixed-citation></ref><ref id="hanspub.28546-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Bogsrud, M.P., Ose, L., Langslet, G., Ottestad, I., Strøm, E.C., Hagve, T.A. and Retterstøl, K. (2010) HypoCol (Red Yeast Rice) Lowers Plasma Cholesterol—A Randomized Placebo Controlled Study. Scandinavian Cardiovascular Journal, 44, 197-200. &lt;br&gt;https://doi.org/10.3109/14017431003624123</mixed-citation></ref><ref id="hanspub.28546-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Dattilo, A.M. and Kris-Etherton, P.M. (1992) Effects of Weight Reduction Onblood Lipids and Lipoproteins: A Meta-Analysis. The American Journal of Clinical Nutrition, 56, 320-328. &lt;br&gt;https://doi.org/10.1093/ajcn/56.2.320</mixed-citation></ref><ref id="hanspub.28546-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Poobalan, A., Aucott, L., Smith, W., Avenell, A., Jung, R., Broom, J. and Grant, A. (2004) Effects of Weight Loss in Overweight/Obese Individuals and Longterm Lipid Outcomes—A Systematic Review. Obesity Reviews, 5, 43-50.  
&lt;br&gt;https://doi.org/10.1111/j.1467-789X.2004.00127.x</mixed-citation></ref><ref id="hanspub.28546-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Hau, M.F., Smelt, A.H.M., Bindels, A.J.G.H., Sijbrands, E.J.G., Van derLaarse, A., Onkenhout, W., Princen, H.M.G., et al. (1996) Effects of Fish Oil on Oxidation Resistance of VLDL in Hypertriglyceridemic Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 16, 1197-1202. &lt;br&gt;https://doi.org/10.1161/01.ATV.16.9.1197</mixed-citation></ref><ref id="hanspub.28546-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Palomäki, A., Malminiemi, K., Solakivi, T. and Malminiemi, O. (1998) Ubiquinone Supplementation during Lovastatin Treatment: Effect on LDL Oxidation Ex Vivo. Journal of Lipid Research, 39, 1430-1437.</mixed-citation></ref><ref id="hanspub.28546-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">lwai, K., Nakaya, N., Kawasaki, Y. and Matsue, H. (2002) Inhibitory Effect of Natto, a Kind of Fermented Soybeans, on LDL Oxidation In Vitro. Journal of Agricultural and Food Chemistry, 50, 3592-3596.  
&lt;br&gt;https://doi.org/10.1021/jf011718g</mixed-citation></ref></ref-list></back></article>